MedTrace Logo

Parkinson's Disease Therapy Using Cell Technology

NCT04146519 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-03-03

No results posted yet for this study

Summary

Treatment of patients with Parkinson's disease using mesenchymal stem cells is a perspective method to influence on the pathogenesis of the disease. At the same time, this is a complex and still insufficiently explored process. Autologous mesenchymal stem cells will be transplanted to 30 patients with Parkinson's disease. The results of the effectiveness of the combined and intravenous routes of mesenchymal stem cells administration on the motor and non-motor symptoms in these patients will be evaluated and compared with the results of control group that received placebo therapy

Conditions

  • Transplantation:Mesenchymal Stem Cell Transplantation

Interventions

BIOLOGICAL

Autologous mesenchymal stem cells

Autologous mesenchymal stem cells

OTHER

Placebo

Saline solution

Sponsors & Collaborators

  • Belarusian Medical Academy of Post-Graduate Education

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2021-12-01
Completion
2021-12-31

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04146519 on ClinicalTrials.gov